---
layout: post
title: "迪哲医药：戈利昔替尼（DZD4205）临床研究数据获选欧洲血液学协会年会口头报告"
date: 2022-05-13 15:45:07 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.688192" data-code="688192|1|1" data-code2="688192|1|23|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.688192&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 688192_0" data-code="K 688192|1|1" data-code2="K 688192|1|23|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>迪哲医药公告，戈利昔替尼(DZD4205)临床研究数据获选2022年第27届欧洲血液学协会年会(EHA)口头报告。 <br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205132378739086>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)